• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: Find Out the Latest Financial Results of Merck Generics - the Major International Generic Manufacturer

Posted on: Friday, 2 June 2006, 15:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c37923) has announced the addition of the Espicom Business Intelligence Ltd report: Merck Generics Company Intelligence Report to their offering.

Our generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the companys active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Topics Covered

INTRODUCTION

Alphapharm

Generics (UK)

Genpharm

Merck Generics (South Africa)

Merck Generiques (France)

Merck Dura

Merck Hoei

McDermott Laboratories (Gerard)

Dey Inc

PRODUCTS

Alphapharm ANDA Approvals, 2002-05

Genpharm ANDA Approvals, 2002-05

Dey ANDA Approvals, 2002-05

Recent product approvals

Zonisamide capsules

Levothyroxine tablets

Alphapharm receives cilostazol ANDA

FINANCIAL RESULTS

Latest Yearly Results, 2005

Merck KGaA Pharmaceutical Sales, 2000-05 (euro millions)

Merck KGaA Pharmaceutical Sales, 2000-05 (% of Total)

Merck KGaA Pharmaceutical Sales, 2001-05 (% Change)

Merck Generics Financial Results, 2003-05 (euro millions)

Merck Generics Sales by Region, 2004-05 (million euros)

Profit after tax of major subsidiaries, 2003-05 (euros million)

Employees of major subsidiaries, 2003-05

Major developments

Expansion of McDermott Laboratories, Ireland

Mergers, acquisitions and agreements

Microbix takes over urokinase production from Genpharm

Merck KGaA purchases Spains Prasfarma

Orbus and Generics (UK) sign cefuroxime axetil licensing and supply agreement

MERCK GENERICS GENERIC COMPANIES ANALYSIS

ii Quarter I, 2006

Inyx selected by Generics (UK) to produce salbutamol asthma inhaler

Acquisition of NM Pharma

Atrix Laboratories

Mohan Generics Unit

Litigation

Dey files Para IV ANDA submission for levalbuterol inhalation solution

Takeda wins patent infringement litigation against ANDA filers for generic Actos

Alphapharm settles US litigation with Forest Laboratories, enters authorised generic agreement

Generics (UK)

Serious Fraud Office investigation

NHS Legal Action, 2004

Summary

The Merck Generics Group was formed as part of the German Merck KGaA group in 1994, and forms part of the company's Pharmaceuticals Division. The company has since grown to become a major international generic manufacturer. It is broadly represented across the world, and claims a leading position in the markets of Australia, France, New Zealand, Portugal, and the United Kingdom.

Merck Generics' research and development strategy is to identify all major products across the world with a patent expiry in the near-future and ensure that they are available for sale in the relevant territories on the day of patent expiry.

Merck Generics' subsidiaries include:

-- Merck Generiques (France)

-- Merck dura (Germany)

-- Merck Generics Italia (Italy)

-- Merck Generics (Netherlands)

-- Merck Generics (Spain)

-- Merck NM (Sweden)

-- Generics (UK)

-- Alphapharm (Australia)

-- Genpharm (Canada)

-- Merck Generics Brazil

-- Genpharm LP (USA)

-- Merck Hoei (Japan)

-- Merck Generics South Africa

-- Dey, inc (USA)

-- McDermott Laboratories (Ireland)

For more information visit http://www.researchandmarkets.com/reports/c37923

Source: Business Wire

More News in this Category